Deciphera Pharmaceuticals Initial Public Offering

Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total gross proceeds of $127.5 million. Deciphera Pharmaceuticals’ common stock is traded on the NASDAQ Global Select Market under the symbol “DCPH.” 

Headquartered in Waltham, Massachusetts, Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance that limit the rate and/or durability of response to existing cancer therapies. The company’s pipeline consists of tumor-targeted and immune-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment. 

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associates Donald Shum and Leigh Katz. Counsel David R. Bauer and associates Bonnie Chen and Jay Frankel provided intellectual property and technology advice. Partner Michael Mollerus provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.